Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Twelve Month, Phase II, Randomized, Open-Label, Multi-Center, Dose-Ranging Study of Weekly ALTU-238 (Somatropin) as Compared With Daily Nutropin AQ (Somatropin) in Prepubertal Children With Growth Hormone Deficiency

NCT00837863 is registered in ClinicalTrials.gov with Altus Pharmaceuticals as lead sponsor.

NCT NCT00837863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00837863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Twelve Month, Phase II, Randomized, Open-Label, Multi-Center, Dose-Ranging Study of Weekly ALTU-238 (Somatropin) as Compared With Daily Nutropin AQ (Somatropin) in Prepubertal Children With Growth Hormone Deficiency
Lead sponsor
Altus Pharmaceuticals
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2009
Completion date
Not reported
Enrollment
36 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

growth hormone deficiency